Refine
Year of publication
Document Type
- Article (5316)
- Doctoral Thesis (1500)
- Part of Periodical (211)
- Conference Proceeding (187)
- Preprint (171)
- Book (86)
- Contribution to a Periodical (67)
- Review (50)
- Working Paper (22)
- Part of a Book (17)
Language
Keywords
- inflammation (80)
- COVID-19 (60)
- SARS-CoV-2 (48)
- apoptosis (38)
- cancer (38)
- glioblastoma (38)
- Inflammation (37)
- breast cancer (34)
- autophagy (29)
- prostate cancer (28)
Institute
- Medizin (7647) (remove)
Background: To investigate patients’ perspectives on polypharmacy and the use of a digital decision support system to assist general practitioners (GPs) in performing medication reviews. Methods: Qualitative interviews with patients or informal caregivers recruited from participants in a cluster-randomized controlled clinical trial (cRCT). The interviews were transcribed verbatim and analyzed using thematic analysis. Results: We conducted 13 interviews and identified the following seven themes: the patients successfully integrated medication use in their everyday lives, used medication plans, had both good and bad personal experiences with their drugs, regarded their healthcare providers as the main source of medication-related information, discussed medication changes with their GPs, had trusting relationships with them, and viewed the use of digital decision support tools for medication reviews positively. No unwanted adverse effects were reported. Conclusions: Despite drug-related problems, patients appeared to cope well with their medications. They also trusted their GPs, despite acknowledging polypharmacy to be a complex field for them. The use of a digital support system was appreciated and linked to the hope that reasons for selecting specific medication regimens would become more comprehensible. Further research with a more diverse sampling might add more patient perspectives.
Background: To assess the potential of radiomic features to quantify components of blood in intraaortic vessels to non-invasively predict moderate-to-severe anemia in non-contrast enhanced CT scans. Methods: One hundred patients (median age, 69 years; range, 19–94 years) who received CT scans of the thoracolumbar spine and blood-testing for hemoglobin and hematocrit levels ± 24 h between 08/2018 and 11/2019 were retrospectively included. Intraaortic blood was segmented using a spherical volume of interest of 1 cm diameter with consecutive radiomic analysis applying PyRadiomics software. Feature selection was performed applying analysis of correlation and collinearity. The final feature set was obtained to differentiate moderate-to-severe anemia. Random forest machine learning was applied and predictive performance was assessed. A decision-tree was obtained to propose a cut-off value of CT Hounsfield units (HU). Results: High correlation with hemoglobin and hematocrit levels was shown for first-order radiomic features (p < 0.001 to p = 0.032). The top 3 features showed high correlation to hemoglobin values (p) and minimal collinearity (r) to the top ranked feature Median (p < 0.001), Energy (p = 0.002, r = 0.387), Minimum (p = 0.032, r = 0.437). Median (p < 0.001) and Minimum (p = 0.003) differed in moderate-to-severe anemia compared to non-anemic state. Median yielded superiority to the combination of Median and Minimum (p(AUC) = 0.015, p(precision) = 0.017, p(accuracy) = 0.612) in the predictive performance employing random forest analysis. A Median HU value ≤ 36.5 indicated moderate-to-severe anemia (accuracy = 0.90, precision = 0.80). Conclusions: First-order radiomic features correlate with hemoglobin levels and may be feasible for the prediction of moderate-to-severe anemia. High dimensional radiomic features did not aid augmenting the data in our exemplary use case of intraluminal blood component assessment.
Die Sonografie wird als primäre Untersuchungsmethode zur Abklärung vielfältiger Krankheitsbilder eingesetzt und hat sich auch in Leitlinien etabliert. Die Rolle der Sonografie in der Geriatrie ist weniger bekannt und nicht systematisch untersucht.
Ziel der Studie war die Evaluierung der Sonografie als routinemäßig eingesetztes Verfahren und erweiterte körperliche Untersuchung bei geriatrischen Patienten in der medizinischen Akutversorgung. Alle sogenannten geriatrischen Assessments und auch die Sonografie als Screening-Untersuchung erfolgten unabhängig von der Symptomatik des geriatrischen Patienten. Die Befunde wurden mit einem hand-held ultrasound device (HHUSD) und einem high-end ultrasound (HEUS) erhoben und dann verglichen. Die HEUS-Ergebnisse wurden als Goldstandard angesehen. Die Untersuchungen mit HEUS erfolgten meist zu einem späteren Zeitpunkt als mit HHUSD; in der Regel in einem Zeitraum von bis zu sieben Tagen.
Es handelt sich um eine prospektive Studie, die 86 Patienten in einem Zeitraum von 10 Monaten eingeschlossen hat. Die Untersucherin und Doktorandin stellte Folgendes dar: Das Abdomen und die basalen Abschnitte des Thorax sowie die Schilddrüse. Zusätzlich erfolgte eine elastografische Untersuchung der Leber mittels FibroScan.
Die Ultraschalluntersuchung war bei 22/86 (25,6 %) Patienten aufgrund der Symptomatik indiziert und erfolgte bei 64/86 (74,4 %) Patienten als Screening, also ohne klinische Fragestellung. Die Indikationen der Untersuchungen waren: Tumorsuche (8/86 (9,3 %)), Anämie (5/86 (5,8 %)), Leberwert-Erhöhung (5/86 (5,8 %)), Dyspnoe (5/86 (5,8 %)), Frage nach Milzpathologien (2/86 (2,3 %)), Gewichtsverlust (1/86 (1,2 %)), Infektfokussuche (1/86 (1,2 %)), Durchfall (1/86 (1,2 %)), Frage nach intraabdominalem Hämatom (1/86 (1,2 %)) und Kontrolle bei bekanntem Bauchaortenaneurysma (1/86 (1,2 %)). Bei einigen Patienten kamen mehrere Fragestellungen vor.
Die Befunde, die am häufigsten gefunden wurden, waren: Cholezystolithiasis (28/86 (32,6 %); mit HHUSD 5 falsch negative Ergebnisse), rechtsseitiger Pleuraerguss (27/86 (31,4 %); 5 falsch positive Ergebnisse mit HHUSD), Schilddrüsenknoten (26/86 (30,2 %); 2 falsch negative und 1 falsch positiver Befunde mit HHUSD), Nierenzysten (24/86 (27,9 %); 6 falsch negative Ergebnisse mit HHUSD) und Fettleber (23/86 (26,7 %); 3 falsch negative Befunde mit HHUSD). Von 64/86 (74,4 %) untersuchten Patienten ergab sich bei 8/86 (9,3 %) eine therapeutische Konsequenz. Die wichtigsten Befunde, die mit HHUSD übersehen wurden waren: 2 zystische Formationen im Pankreas (2/86 (2,3 %); mit HEUS insgesamt (6/86 (7,0 %)), eine Lebezirrhose (mit HEUS 2/86 (2,3 %)), eine Choledocholithiasis (1/86 (1,2 %); mit HEUS 2/86 (2,3 %)) und ein Lungeninfiltrat (1/86 (1,2 %); mit HEUS 2/86 (2,3 %)). Alle übersehenen Befunde hatten keine dringende therapeutische Konsequenz, so dass die point of care Sonografie (POCUS) hier ausreichend war, um die „ja/nein“-Fragen zu klären.
Bei 65/86 (75,6 %) Patienten war eine Messung der Lebersteifigkeit mittels FibroScan erfolgreich.
Es gab keine Interobserver-Variabilität. Die Untersucherin war eine Fachärztin für Innere Medizin aber keine DEGUM-ausgebildete Ultraschallerin.
Insgesamt zeigte sich eine ausreichende bis gute Übereinstimmung der erhobenen Befunde zwischen HHUSD und HEUS. Die POCUS-Untersuchung lieferte in den meisten Fällen eine Antwort auf die häufigsten Fragestellungen in der Geriatrie (wie Hydratationsstatus, Harnverhalt). Weiterhin konnte die Behandlung bei zufällig gescreenten Patienten optimiert werden. Zur Bestimmung der Organgröße konnte ebenfalls eine gute Korrelation der beiden Geräte festgestellt werden, so dass sich die alleinige Untersuchung mit HHUSD in diesen Fällen ausreichend gezeigt hätte. Ein routinemäßiger Einsatz der Sonografie in der Geriatrie muss in weiteren Studien untersucht werden. Da es sich bei geriatrischen Patienten um multimorbide Patienten mit entsprechend angepassten therapeutischen Zielen handelt, hatten mehrere der erhobenen Befunde in dieser Studie zum Zeitpunkt der geriatrischen Behandlung keine therapeutische Konsequenz.
Mycophenolate-Mofetil (MMF) clinically used as CellCept is inserted as immunosuppressive xenobiotic drug for preventing transplantate rejection. It is well known that MMF works selectively through inhibiting the IMPDH which is an essential enzyme in the de novo pathway for biosynthesis of guanosine Nukleotides.
In this study, we investigated the effects of MMF on the astrocytes, because astrocytes are important glial cells of the CNS with various functions in the healthy tissue, such as being involved in the neuronal differentiation, axonal growth and regulation of the environmental composition. They also build up the scared tissue during acute CNS lesions by releasing neurotoxic substances such as NO and different inflammatory Zytokines, e.g. IL-1ß and TNF-a, which even influence the microglial cell proliferation, migration and activity. Therefore, astrocytes are impressingly involved in the extent of the neuronal damage.
Our observations revealed an influence of astrocytic proliferation dependent on the concentration of the serum (10%, 5%, 2%, 1% and serum free medium) used for the in vitro cultivation: the more the serum part in the medium the more the extent of the cell proliferation. The proliferation of astrocytes cultured in serum free medium can be increased by Corticotropin Releasing Factor (CRF) 10µM and Guanosine application. Dose-dependent MMF led to a suppression of the astrocytic proliferation which is antagonisable with Guanosine only.
The number of the isolated proliferating astrocytes labeled by BrdU was significantly reduced after simultaneous treatment with serum (10% or 1%) and dose-dependent MMF (10µg/ ml, 1µg/ ml and 0,1µg/ ml) application, whereas LPS showed no effect on the proliferating rate. But, as measured by ELISA, with LPS conditioned medium contained relevant amounts of TNF-a and NO, but surprisingly not of IL-1ß. There were a significant reduction of cytokine and NO amounts determined in the astrocytic conditioned medium treated only with MMF dependent of the concentration (10µg/ml, 1µg/ml and 0,1µg/ml). Even the simultaneous treatment with LPS and MMF revealed compared to the LPS stimulated astrocytic group a measurable significant decrease of TNF-a. The treatment of the astrocytic cultures with guanosine lifted up the effects of MMF on TNF-a secretion. Therefore, we conclude, that the immunosuppressive drug MMF might have a neuroprotective and scar formation modulating effect through the antiproliferative potency on astrocytic cells and modulating character of the microenvironment by influencing the TNF-a secretion. Moreover, these regulatory effect on microglial cells are described as suppression (Hailer NP,Wirjatijana F,Roser N,Hirschebeth GT,Korf HW,Dehghani F,2001).
Background: Gait kinematics after total hip replacement only partly explain the differences in the joint moments in the frontal plane between hip osteoarthritis patients after hip replacement and healthy controls. The goal of this study was to determine if total hip replacement surgery affects radiological leg alignment (Hip-Knee-Shaft-Angle, femoral offset, Neck-Shaft-Angle and varus/valgus alignment) and which of these parameters can explain the joint moments, additionally to the gait kinematics.
Methods: 22 unilateral hip osteoarthritis patients who were scheduled for total hip replacement were included in the study. Preoperatively and 1 year postoperatively all patients had biplanar radiographic examinations and 3D gait analysis.
Results: The operated leg showed significantly (P < 0.05) more varus (1.1°) as well as a larger femoral offset (+ 8 mm) and a larger Hip-Knee-Shaft-Angle (+ 1.3°) after total hip replacement; however no significant differences in the joint moments in the frontal plane compared to healthy controls were found. The hip moment (first half of stance) and the knee moments (first and second half of stance) were mostly determined by the varus/valgus alignment (29% and respectively 36% and 35%). The combination with a kinematic parameter (knee range of motion, foot progression angle) increased the predictive value for the knee moments.
Conclusion: In our patient group the joint moments after total hip replacement did not differ from healthy controls, whereas radiological leg alignment parameters changed significantly after the total hip replacement. A combination of these radiological leg parameters, especially the varus alignment, and the deviating kinematics explain the joint moments in the frontal plane during gait after total hip replacement surgery. For surgeons it is important not to create too much of a structural varus alignment by implanting the new hip joint as varus alignment can increase the knee adduction moment and the risk for osteoarthritis of the medial knee compartment.
Trial registration: This study was retrospectively registered with DRKS (German Clinical Trials Register) under the number DRKS00015053. Registered 1st of August 2018.
Zielstellung: Es sollte im Rahmen dieser Arbeit geprüft werden ob (1) ein Zusammenhang zwischen einer radiologischen Beinlängendifferenz und einer veränderten Hüft- bzw. Kniegelenksbelastung bei Coxarthrosepatienten besteht. Des Weiteren galt es zu prüfen (2) ob die radiologisch-anatomische Beinachse bei Coxarthrosepatienten einen Einfluss auf die Gelenksbelastung von Hüfte und Knie habe und (3) ob sich in diesem Zusammenhang Unterschiede zwischen unilateral und bilateral betroffenem Patientenkollektiv darstellen ließe.
Hintergründe: Es konnte bereits gezeigt werden, dass Coxarthrosepatienten ein verändertes Gangbild aufweisen. Diese Veränderungen sind mitverantwortlich für eine veränderete Gelenkbelastung sowohl in Knie als auch Hüfte, sowohl im Vergleich zwischen betroffener und nicht betroffener Seite als auch im Vergleich zu hüftgesunden Normprobanden. Insbesondere bezüglich der Kniegelenksbelastung konnte bei den Betroffenen ein reduziertes Knieadduktionsmoment (KAM) während der Standphase nachgewiesen werden. Dies steht im Einklang mit der Beobachtung, dass Coxarthrosepatienten vermehrt eine laterale Kniearthrose auf der ipsilateralen Seite entwickeln. Coxarthrosepatienten zeigten darüber hinaus eine veränderte Beinachse, mit einer Tendenz hin zu einer Valgusfehlstellung. In wieweit insbesondere die proximale Beinachse einen Einfluss auf die alterierten Gelenkmomente hat, bleibt bislang jedoch offen. Zu bilateralen Patienten sind darüber hinaus nur wenige Daten vorliegend.
Methoden: Um die oben genannten Hypothesen zu prüfen wurden bei insgesamt 29 Patienten, bei welchen die Indikation für eine Hüfttotalendoprothese aufgrund einer fortgeschrittenen Coxarthrose gestellt wurde, eine instrumentelle Bewegungsanalyse sowie eine biplanare EOSRöntgenaufnahme, welche in diesem Zusammenhang die konventionelle präoperative Planungsaufnahme ersetzte, durchgeführt. Anschließend wurden die Daten, die aus der 3D EOS Rekonstruktion über die Beinachse gewonnen wurden, sowie die Ergebnisse der Bewegungsanalyse mit bereits zuvor erhobenen Normdaten sowie untereinander verglichen und statistisch analysiert.
Ergebnisse: Es zeigte sich, dass die Patienten eine bis auf MFA nicht von der Norm abweichende Beinachse hatten. Die bilateralen zeigten eine signifikant größere Beinlängendifferenz als die Norm, die unilateralen Patienten jedoch diesbezüglich keine Abweichung. Insgesamt zeigten die Patienten ein verändertes Gangbild, welches weitgehend den bereits in der Literatur beschriebenen Veränderungen entsprach.
Bezüglich der Gelenkmomente zeigte sich ein im Vergleich zur Norm erniedrigtes KAM 2, die übrigen Gelenkmomente zeigten keine Abweichungen von der Norm.
Es zeigten sich weder für die Beinachse noch für die Gelenkmomente signifikante Unterschiede zwischen unilateralem und bilateralem Patientenkollektiv.
Die unilateralen Patienten als gesamtes zeigten keine Korrelationen mit der absoluten Beinlängendifferenz. In einer unilateralen Subgruppe, in der die betroffene Seite länger war, konnte eine inverse Korrelation mit HAM 1 und HAM 2 gefunden werden.
KAM 1 und KAM 2 korrelierten signifikant mit allen Beinachsenparametern. In einer schrittweisen Regressionsanalyse mit HKA, FO und MFA konnten damit 68% der KAM 1 Alterationen und 57,5 % der Veränderungen von KAM 2 erklärt werden. HAM 1 und HAM 2 zeigten jeweils eine signifikante Korrelation mit MFA.
Schlussfolgerung: Die vorliegenden Ergebnisse zeigen, dass die Beinachse, insbesondere das Offset, einen Teil der Veränderungen der Kniegelenksbelastung erklären. Eine intraoperative Vergrößerung des Offsets und damit eine Varisierung der Beinachse könnte möglicherweise so zu einer Normalisierung der Kniegelenksbelastung führen.
Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) in the HCC4006rErlo0.5 NSCLC cell line adapted to erlotinib as a model of acquired drug resistance. Constitutive CIP2A resulted in a constitutive activation of Akt signaling. The proteasome inhibitor bortezomib was able to reduce CIP2A levels, which resulted in an activation of protein phosphatase 2A and deactivation of Akt. Combination experiments with erlotinib and bortezomib revealed a lack of interaction between the two drugs. However, the effect size of bortezomib was higher in HCC4006rErlo0.5, compared to the erlotinib-sensitive HCC4006 cells, as indicated by an increase in Emax (0.911 (95%CI 0.867–0.954) vs. 0.585 (95%CI 0.568–0.622), respectively) and decrease in EC50 (52.4 µM (95%CI 46.1–58.8 µM) vs. 73.0 µM (95%CI 60.4–111 µM), respectively) in the concentration–effect model, an earlier onset of cell death induction, and a reduced colony surviving fraction (0.38 ± 0.18 vs. 0.95 ± 0.25, respectively, n = 3, p < 0.05). Therefore, modulation of CIP2A with bortezomib could be an interesting approach to overcome drug resistance to erlotinib treatment in NSCLC.
Background: Non-clear cell renal cell cancers (nccRCC) are rare entities, and the optimal therapy in metastatic disease has still to be defined. Methods: In this small prospectively randomized phase IIa multicenter trial, we investigated temsirolimus (TEM) versus sunitinib (SUN) as first-line therapy in patients with metastatic nccRCC. The patients were randomized 1:1 to either TEM in a dose of 25 mg i.v. once a week or SUN with 50 mg p.o. daily for 4 weeks on and 2 weeks off. Primary endpoint was progression-free survival (PFS). In total, 22 patients were included with predominantly papillary RCC (16/22) followed by chromophobe RCC and others. Results: The male to female ratio was 16:6. The tumor control rate (CR + PR + SD) was 58% for TEM and 90% for SUN-treated patients. There was also a trend for improved PFS with 9.3 versus 13.2 months (HR 1.64; 95% CI 0.65–4.18) in favor of SUN. There was no trend for overall survival. Conclusions: Despite this trial had to be terminated earlier due to low recruitment, the results match the other studies published so far with the mTOR inhibitor everolimus and SUN, which show a trend in favor of SUN for ORR and PFS.
Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.
Treatment options of locoregional recurrent head and neck squamous cell cancer (HNSCC) include both local strategies as surgery or re-radiotherapy and systemic therapy. In this prospective, multi-center, non-interventional study, patients were treated either with platinum-based chemotherapy and cetuximab (CT + Cet) or re-radiotherapy and cetuximab (RT + Cet). In the current analysis, progression-free survival (PFS) and overall survival (OS) were compared in patients with locoregional recurrence. Four hundred seventy patients were registered in 97 German centers. After exclusion of patients with distant metastases, a cohort of 192 patients was analyzed (129 CT + Cet, 63 RT + Cet). Radiotherapy was delivered as re-irradiation to 70% of the patients. The mean radiation dose was 51.8 Gy, whereas a radiation dose of ≥60 Gy was delivered in 33% of the patients. Chemotherapy mainly consisted of cisplatin/5-flurouracil (40%) or carboplatin/5-flurouracil (29%). The median PFS was 9.2 months in the RT + Cet group versus 5.1 months in the CT + Cet group (hazard ratio for disease progression or death, 0.40, 95% CI, 0.27–0.57, p < 0.0001). Median OS was 12.8 months in the RT + Cet group versus 7.9 months in the CT + Cet group (hazard ratio for death, 0.50, 95% CI, 0.33–0.75, p = 0.0008). In conclusion, radiotherapy combined with cetuximab improved survival compared to chemotherapy combined with cetuximab in locally recurrent HNSCC.
Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (OdomzoTM, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be translated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.
Background: A major disadvantage of current spacers for two-stage revision total knee arthroplasty (R-TKA) is the risk of (sub-) luxation during mobilization in the prosthesis-free interval, limiting their clinical success with detrimental consequences for the patient. The present study introduces a novel inverse spacer, which prevents major complications, such as spacer (sub-) luxations and/or fractures of spacer or bone. Methods: The hand-made inverse spacer consisted of convex tibial and concave femoral components of polymethylmethacrylate bone cement and was intra-operatively molded under maximum longitudinal tension in 5° flexion and 5° valgus position. Both components were equipped with a stem for rotational stability. This spacer was implanted during an R-TKA in 110 knees with diagnosed or suspected periprosthetic infection. Postoperative therapy included a straight leg brace and physiotherapist-guided, crutch-supported mobilization with full sole contact. X-rays were taken before and after prosthesis removal and re-implantation. Results: None of the patients experienced (sub-) luxations/fractures of the spacer, periprosthetic fractures, or soft tissue compromise requiring reoperation. All patients were successfully re-implanted after a prosthesis-free interval of 8 weeks, except for three patients requiring an early exchange of the spacer due to persisting infection. In these cases, the prosthetic-free interval was prolonged for one week. Conclusion: The inverse spacer in conjunction with our routine procedure is a safe and cost-effective alternative to other articulating or static spacers, and allows crutch-supported sole contact mobilization without major post-operative complications. Maximum longitudinal intra-operative tension in 5° flexion and 5° valgus position appears crucial for the success of surgery.
Background: Clinical practice guidelines for patients with primary biliary cholangitis (PBC) have been recently revised and implemented for well-established response criteria to standard first-line ursodeoxycholic acid (UDCA) therapy at 12 months after treatment initiation for the early identification of high-risk patients with inadequate treatment responses who may require treatment modification. However, there are only very limited data concerning the real-world clinical management of patients with PBC in Germany. Objective: The aim of this retrospective multicenter study was to evaluate response rates to standard first-line UDCA therapy and subsequent Second-line treatment regimens in a large cohort of well-characterized patients with PBC from 10 independent hepatological referral centers in Germany prior to the introduction of obeticholic acid as a licensed second-line treatment option. Methods: Diagnostic confirmation of PBC, standard first-line UDCA treatment regimens and response rates at 12 months according to Paris-I, Paris-II, and Barcelona criteria, the follow-up cut-off alkaline phosphatase (ALP) ≤ 1.67 × upper limit of normal (ULN) and the normalization of bilirubin (bilirubin ≤ 1 × ULN) were retrospectively examined between June 1986 and March 2017. The management and hitherto applied second-line treatment regimens in patients with an inadequate response to UDCA and subsequent response rates at 12 months were also evaluated. Results: Overall, 480 PBC patients were included in this study. The median UDCA dosage was 13.2 mg UDCA/kg bodyweight (BW)/d. Adequate UDCA treatment response rates according to Paris-I, Paris-II, and Barcelona criteria were observed in 91, 71.3, and 61.3% of patients, respectively. In 83.8% of patients, ALP ≤ 1.67 × ULN were achieved. A total of 116 patients (24.2%) showed an inadequate response to UDCA according to at least one criterion. The diverse second-line treatment regimens applied led to significantly higher response rates according to Paris-II (35 vs. 60%, p = 0.005), Barcelona (13 vs. 34%, p = 0.0005), ALP ≤ 1.67 × ULN and bilirubin ≤ 1 × ULN (52.1 vs. 75%, p = 0.002). The addition of bezafibrates appeared to induce the strongest beneficial effect in this cohort (Paris II: 24 vs. 74%, p = 0.004; Barcelona: 50 vs. 84%, p = 0.046; ALP < 1.67 × ULN and bilirubin ≤ 1 × ULN: 33 vs. 86%, p = 0.001). Conclusion: Our large retrospective multicenter study confirms high response rates following UDCA first-line standard treatment in patients with PBC and highlights the need for close monitoring and early treatment modification in high-risk patients with an insufficient response to UDCA since early treatment modification significantly increases subsequent response rates of these patients.
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance (AR). A multinational, multicenter retrospective study in patients aged ≤ 18 years, treated with chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant to meropenem. Methicillin-resistance was observed in 17% of S. aureus and vancomycin resistance in 40% of E. faecium. Previous exposure to antibiotics, especially to carbapenems, was significantly associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant S. aureus was associated with BSI due to this pathogen. Hematological malignancies, neutropenia and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need of ICU admission were significantly associated with mortality. Center-level variation showed a greater impact on AR, while patient-level variation had more effect on ICU admission and mortality. Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI. Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a significant role for the treating center too. The significant evidence of center-level variations on AR, ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection control programs.
Simple Summary: Tooth roots are increasingly applied for bone reconstruction before implant placement. Growth factors stored in the dentin are assumed to enhance bone regeneration, however, the evidence is low. To this aim, collagen membranes were coated with dentin lysates obtained from extracted porcine teeth or remain untreated. The collagen membranes were tested for their capacity to stimulate bone formation in rat calvarial bone defects. After four weeks of healing, micro-computed tomography and histological analyses revealed that dentin lysates coating had no significant impact on the rather strong bone regeneration reaching a nearly complete defect closure even in untreated defects. It can thus be concluded that dentin lysates do not hinder bone regeneration. Conclusions concerning a possible stimulation of bone regeneration by dentin lysates should not be drawn.
Abstract: Autogenous tooth roots are increasingly applied as a grafting material in alveolar bone augmentation. Since tooth roots undergo creeping substitution similar to bone grafts, it can be hypothesized that osteoclasts release the growth factors stored in the dentin thereby influencing bone formation. To test this hypothesis, collagen membranes were either soaked in acid dentin lysates (ADL) from extracted porcine teeth or serum–free medium followed by lyophilization. Thereafter, these membranes covered standardized 5-mm-diameter critical-size defects in calvarial bone on rats. After four weeks of healing, micro-computed tomography and histological analyses using undecalcified thin ground sections were performed. Micro-computed tomography of the inner 4.5 mm calvaria defects revealed a median bone defect coverage of 91% (CI: 87–95) in the ADL group and 94% (CI: 65–100) in the control group, without significant differences between the groups (intergroup p > 0.05). Furthermore, bone volume (BV) was similar between ADL group (5.7 mm3, CI: 3.4–7.1) and control group (5.7 mm3, CI: 2.9–9.7). Histomorphometry of the defect area confirmed these findings with bone area values amounting to 2.1 mm2 (CI: 1.2–2.6) in the ADL group and 2.0 mm2 (CI: 1.1–3.0) in the control group. Together, these data suggest that acid dentin lysate lyophilized onto collagen membranes failed to modulate the robust bone formation when placed onto calvarial defects.
The rapid detection of pathogens in infected wounds can significantly improve the clinical outcome. Wound exudate, which can be collected in a non-invasive way, offers an attractive sample material for the detection of pathogens at the point-of-care (POC). Here, we report the development of a nucleic acid lateral flow immunoassay for direct detection of isothermally amplified DNA combined with fast sample preparation. The streamlined protocol was evaluated using human wound exudate spiked with the opportunistic pathogen Pseudomonas aeruginosa that cause severe health issues upon wound colonization. A detection limit of 2.1 × 105 CFU per mL of wound fluid was achieved, and no cross-reaction with other pathogens was observed. Furthermore, we integrated an internal amplification control that excludes false negative results and, in combination with the flow control, ensures the validity of the test result. The paper-based approach with only three simple hands-on steps has a turn-around time of less than 30 min and covers the complete analytical process chain from sample to answer. This newly developed workflow for wound fluid diagnostics has tremendous potential for reliable pathogen POC testing and subsequent target-oriented therapy.
Causality assessment in liver injury induced by drugs and herbs remains a debated issue, requiring innovation and thorough understanding based on detailed information. Artificial intelligence (AI) principles recommend the use of algorithms for solving complex processes and are included in the diagnostic algorithm of Roussel Uclaf Causality Assessment Method (RUCAM) to help assess causality in suspected cases of idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI). From 1993 until the middle of 2020, a total of 95,865 DILI and HILI cases were assessed by RUCAM, outperforming by case numbers any other causality assessment method. The success of RUCAM can be traced back to its quantitative features with specific data elements that are individually scored leading to a final causality grading. RUCAM is objective, user friendly, transparent, and liver injury specific, with an updated version that should be used in future DILI and HILI cases. Support of RUCAM was also provided by scientists from China, not affiliated to any network, in the results of a scientometric evaluation of the global knowledge base of DILI. They highlighted the original RUCAM of 1993 and their authors as a publication quoted the greatest number of times and ranked first in the category of the top 10 references related to DILI. In conclusion, for stakeholders involved in DILI and HILI, RUCAM seems to be an effective diagnostic algorithm in line with AI principles.
The aim of this study was to evaluate the clinical and microbiological effects of subgingival instrumentation (SI) alone or combined with either local drug delivery (LDD) or photodynamic therapy (PDT) in persistent/recurrent pockets in patients enrolled in supportive periodontal therapy (SPT). A total of 105 patients enrolled in SPT were randomly treated as follows: group A (n = 35): SI +PDT and 7 days later 2nd PDT; group B (n = 35): SI+LDD; group C (n = 35): SI (control). Prior intervention, at 3 and 6 months after therapy, probing pocket depths, clinical attachment level, number of treated sites with bleeding on probing (n BOP), full mouth plaque and bleeding scores (gingival bleeding index, %BOP) were recorded. At the same time points, 8 periodontopathogens were quantitatively determined. All three treatments resulted in statistically significant improvements (p < 0.05) of all clinical parameters without statistically significant intergroup differences (p > 0.05). Several bacterial species were reduced in both test groups, with statistically significantly higher reductions for LDD compared to PDT and the control group. In conclusion, the present data indicate that: (a) In periodontal patients enrolled in SPT, treatment of persistent/recurrent pockets with SI alone or combined with either PDT or LDD may lead to comparable clinical improvements and (b) the adjunctive use of LDD appears to provide better microbiological improvements for some periodontal pathogens than SI alone or combined with PDT.
Simple Summary: Renal insufficiency is frequently seen in newly diagnosed multiple myeloma and can be due to the disease itself but also caused by medical interventions or infections. Patients with severe renal insufficiency are known to have an adverse prognosis, but recently, it was shown that even moderately impaired kidney function can have long-term sequelae. Achieving quick disease control by effective antimyeloma therapy can lead to the recovery of renal function. We investigated the kidney-specific variables in a large cohort of 770 myeloma patients receiving three different three-drug regimens for initial myeloma treatment to learn more about the differential effects on kidney function in an early disease phase. All regimens had a positive impact on kidney function without a difference in the proportion of patients who reached normal renal function after three cycles. Interestingly, patients who received bortezomib, lenalidomide, and dexamethasone tended to have higher risk for a worse renal function following induction when compared to the initial values.
Abstract: Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.